Mirtazapin Bluefish (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonises 5‑HT2 and 5‑HT3 receptors and strongly blocks H1 histamine receptors, resulting in enhanced neurotransmission that alleviates depressive symptoms.

The appropriate dose of Mirtazapin Bluefish is determined by the treating physician based on the individual’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative treatments when appropriate. Women who are pregnant or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This mechanism often results in pronounced sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those who need to avoid sedation.

Mirtazapin Bluefish should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

The medication is taken orally, usually once daily in the evening due to its sedative properties. It should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hepatic impairment, significant weight gain, and the potential for increased suicidal thoughts, especially during the initial weeks of therapy. Patients should be monitored closely for any signs of these conditions.

Mirtazapin Bluefish is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and it should be avoided in individuals currently taking monoamine oxidase inhibitors. Caution is also advised for patients with severe liver disease or uncontrolled hypertension.